Relative and disease-free survival for breast cancer in relation to subtype: A population-based study

Pamela Minicozzi, Francesca Bella, Angela Toss, Adriano Giacomin, Mario Fusco, Maurizio Zarcone, Rosario Tumino, Fabio Falcini, Rosaria Cesaraccio, Giuseppa Candela, Francesco La Rosa, Massimo Federico, Milena Sant

Research output: Contribution to journalArticle

Abstract

Purpose: No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient. Methods: Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003-2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated. Results: Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women

Original languageEnglish
Pages (from-to)1569-1577
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Volume139
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Disease-Free Survival
Breast Neoplasms
Population
Neoplasms
Recurrence
Epidermal Growth Factor
Progesterone
Registries
Estrogens
Neoplasm Metastasis

Keywords

  • Breast cancer
  • HER2
  • Hormone receptor
  • Ki67
  • Population-based study
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relative and disease-free survival for breast cancer in relation to subtype : A population-based study. / Minicozzi, Pamela; Bella, Francesca; Toss, Angela; Giacomin, Adriano; Fusco, Mario; Zarcone, Maurizio; Tumino, Rosario; Falcini, Fabio; Cesaraccio, Rosaria; Candela, Giuseppa; La Rosa, Francesco; Federico, Massimo; Sant, Milena.

In: Journal of Cancer Research and Clinical Oncology, Vol. 139, No. 9, 09.2013, p. 1569-1577.

Research output: Contribution to journalArticle

Minicozzi, P, Bella, F, Toss, A, Giacomin, A, Fusco, M, Zarcone, M, Tumino, R, Falcini, F, Cesaraccio, R, Candela, G, La Rosa, F, Federico, M & Sant, M 2013, 'Relative and disease-free survival for breast cancer in relation to subtype: A population-based study', Journal of Cancer Research and Clinical Oncology, vol. 139, no. 9, pp. 1569-1577. https://doi.org/10.1007/s00432-013-1478-1
Minicozzi, Pamela ; Bella, Francesca ; Toss, Angela ; Giacomin, Adriano ; Fusco, Mario ; Zarcone, Maurizio ; Tumino, Rosario ; Falcini, Fabio ; Cesaraccio, Rosaria ; Candela, Giuseppa ; La Rosa, Francesco ; Federico, Massimo ; Sant, Milena. / Relative and disease-free survival for breast cancer in relation to subtype : A population-based study. In: Journal of Cancer Research and Clinical Oncology. 2013 ; Vol. 139, No. 9. pp. 1569-1577.
@article{3381797675044528a87c934a10a85487,
title = "Relative and disease-free survival for breast cancer in relation to subtype: A population-based study",
abstract = "Purpose: No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient. Methods: Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003-2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated. Results: Luminal A cancers were 42 {\%} of the total, luminal B 27 {\%}, luminal-HER2 14 {\%}, triple-negative 11 {\%}, and HER2-enriched 7 {\%}. For non-metastatic (3,302) cases, 4 and 7 {\%} developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women",
keywords = "Breast cancer, HER2, Hormone receptor, Ki67, Population-based study, Survival",
author = "Pamela Minicozzi and Francesca Bella and Angela Toss and Adriano Giacomin and Mario Fusco and Maurizio Zarcone and Rosario Tumino and Fabio Falcini and Rosaria Cesaraccio and Giuseppa Candela and {La Rosa}, Francesco and Massimo Federico and Milena Sant",
year = "2013",
month = "9",
doi = "10.1007/s00432-013-1478-1",
language = "English",
volume = "139",
pages = "1569--1577",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Relative and disease-free survival for breast cancer in relation to subtype

T2 - A population-based study

AU - Minicozzi, Pamela

AU - Bella, Francesca

AU - Toss, Angela

AU - Giacomin, Adriano

AU - Fusco, Mario

AU - Zarcone, Maurizio

AU - Tumino, Rosario

AU - Falcini, Fabio

AU - Cesaraccio, Rosaria

AU - Candela, Giuseppa

AU - La Rosa, Francesco

AU - Federico, Massimo

AU - Sant, Milena

PY - 2013/9

Y1 - 2013/9

N2 - Purpose: No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient. Methods: Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003-2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated. Results: Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women

AB - Purpose: No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient. Methods: Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003-2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated. Results: Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women

KW - Breast cancer

KW - HER2

KW - Hormone receptor

KW - Ki67

KW - Population-based study

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84882660852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882660852&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1478-1

DO - 10.1007/s00432-013-1478-1

M3 - Article

C2 - 23892409

AN - SCOPUS:84882660852

VL - 139

SP - 1569

EP - 1577

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 9

ER -